89bio (ETNB) Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last twelve months. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ETNB shares.
View ETNB analyst ratings or view top-rated stocks.

7 brokers have issued twelve-month target prices for 89bio's stock. Their ETNB share price forecasts range from $24.00 to $50.00. On average, they predict the company's stock price to reach $34.00 in the next twelve months. This suggests a possible upside of 92.2% from the stock's current price.
View analysts price targets for ETNB or view top-rated stocks among Wall Street analysts.

89bio's stock was trading at $12.73 at the start of the year. Since then, ETNB shares have increased by 39.0% and is now trading at $17.69.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ETNB earnings forecast.

89bio, Inc. (NASDAQ:ETNB) posted its quarterly earnings data on Friday, March, 10th. The company reported ($0.48) EPS for the quarter, beating analysts' consensus estimates of ($0.63) by $0.15.

ETFs with the largest weight of 89bio (NASDAQ:ETNB) stock in their portfolio include AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), SPDR S&P Biotech ETF (XBI), Invesco Raymond James SB-1 Equity ETF (RYJ), Harbor Health Care ETF (MEDI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), ALPS Medical Breakthroughs ETF (SBIO), Harbor Disruptive Innovation ETF (INNO) and Invesco Nasdaq Biotechnology ETF (IBBQ).

Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), Raytheon Technologies (RTX), Alibaba Group (BABA), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO).

(ETNB) raised $70 million in an IPO on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

89bio trades on the NASDAQ under the ticker symbol "ETNB."

89bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include State Street Corp (4.21%), Federated Hermes Inc. (3.49%), Suvretta Capital Management LLC (3.03%), Boxer Capital LLC (2.88%), BVF Inc. IL (2.53%) and BlackRock Inc. (1.71%). Insiders that own company stock include Gregory Grunberg, Longitude Capital Partners Iii, Michael R Hayden, Ollin B Sykes, Orbimed Advisors Llc, Quoc Le-Nguyen, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins.
View institutional ownership trends.

Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ETNB stock can currently be purchased for approximately $17.69.

89bio (NASDAQ:ETNB) has a market capitalization of $1.29 billion. The company earns $-102,030,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis.

89bio's mailing address is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. The official website for the company is www.89bio.com. The company can be reached via phone at 415-432-9270 or via email at investors@89bio.com.